Eton Pharmaceuticals (Eton Pharmaceuticals) EPS (Basic) : $0.04 (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Eton Pharmaceuticals EPS (Basic)?

Eton Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was $-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.04.

Eton Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.04.

Eton Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was $-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was 0.04.

During the past 3 years, the average EPS without NRI Growth Rate was 68.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 57.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Eton Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 73.40% per year. The lowest was 29.60% per year. And the median was 68.90% per year.

Eton Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Eton Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eton Pharmaceuticals EPS (Basic) Chart

Eton Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-1.03

-1.33

-0.08

-0.36

-0.04

Eton Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial															-0.10	0.18	-0.02	-0.09	-0.03

Eton Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Eton Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.936	-	0)	/	25.645
	=	-0.04

Eton Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.811	-	0)	/	25.763
	=	-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04

Eton Pharmaceuticals (NAS:ETON) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Eton Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Eton Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Eton Pharmaceuticals (Eton Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eton Pharmaceuticals Inc (NAS:ETON) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278

Website

https://www.etonpharma.com

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development.

Executives

David Krempa	officer: Chief Business Officer	29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Sean Brynjelsen	director, officer: President & CEO	C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
James R. Gruber	officer: Chief Financial Officer	618 AMES STREET, LIBERTYVILLE IL 60048
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
William Wilson Troutman	officer: CFO, Treasurer & Secretary	21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Imprimis Pharmaceuticals, Inc.	10 percent owner	102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215
Jennifer Mckie Adams	director	5410 TENNESSEE AVE, NASHVILLE TN 37209
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Norbert G Riedel	director	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Mark L Baum	director	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121